Filter your results
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC networkNeuro-Oncology, 2016, 18 (9), pp.1297-1303. ⟨10.1093/neuonc/now033⟩
Journal articles
hal-01290413v1
|
||
|
Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSAAnnals of Oncology, 2016, 27 (7), pp.1349-50. ⟨10.1093/annonc/mdw138⟩
Journal articles
hal-01295653v1
|
||
|
Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of ageBritish Journal of Haematology, 2016, 174 (6), pp.887-898. ⟨10.1111/bjh.14140⟩
Journal articles
hal-01331987v1
|